Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: October 4, 2025 (Event Date); Signed October 9, 2025
Reporting Period: Specific event reporting for October 2025.
Business Context: The Company is an emerging growth company focused on clinical development. This filing reports the entry into a strategic partnership to expand clinical trial operations into the United Arab Emirates (UAE).
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or balance sheet data. The only financial figures disclosed relate to a specific contractual commitment:
- Contract Value (Initial Work Order): Approximately $2.4 million in service fees plus $0.1 million in pass-through costs.
- Payment Terms: Payable in four milestone-based installments through study completion.
- Debt and Liquidity: The filing text does not provide a clear value for current debt levels or liquidity positions.
Material Changes
The primary material change reported is the execution of a Master Services Agreement (MSA) with Insights Pharmaceutical Research LLC ("IROS"), a contract research organization (CRO) based in the UAE and an affiliate of Group 42 Holding Ltd. and Mubadala Investment Company PJSC. Key changes include:
- Geographic Expansion: Establishment of a framework to conduct clinical trials in the UAE.
- Operational Structure: The MSA will be transferred to the Company's controlled UAE subsidiary, NuroCure, upon its incorporation.
- Scope of Services: IROS will handle regulatory submissions, site selection, clinical monitoring, data management, and trial reporting under Good Clinical Practice guidelines.
Guidance, Outlook, and Risks
Outlook and Strategic Developments:
- The Company announced two major strategic developments solidifying its Middle East expansion via a press release dated October 9, 2025 (Exhibit 99.1).
- Specific Study: The initial work order covers a multi-site, randomized Phase 2b/3 study evaluating intranasal NEO100 in patients with progressive or recurrent Grade III Astrocytomas and Glioblastoma Multiforme (GBM).
- Intellectual Property: The Company retains all rights to clinical data, IP, and regulatory filings arising from the studies.
Risks and Contingencies:
- Regulatory Compliance: Operations must comply with both UAE and FDA regulations.
- Legal Jurisdiction: The agreement is governed by the laws of the Abu Dhabi Global Market.
- Subsidiary Formation: Full transfer of the MSA is contingent upon the completion of the incorporation of the NuroCure subsidiary.
Investor Verification Checklist
- Verify the incorporation status of the UAE subsidiary, NuroCure, to confirm the transfer of the MSA.
- Review the full text of the Master Services Agreement (Exhibit 10.1) for specific termination rights and liability caps.
- Confirm the timeline for the Phase 2b/3 study milestones to assess cash flow impact.
- Examine the October 9, 2025 press release (Exhibit 99.1) for details on the second strategic development mentioned in Item 7.01.
- Monitor future filings for updates on the $2.5 million total budget utilization and any additional work orders under the MSA.